Carpal tunnel syndrome patients at increased risk of heart failure, amyloidosis
Denmark: Patients undergoing surgery for the treatment of carpal tunnel syndrome (CTS) are at increased risk of developing amyloidosis and heart failure (HF), finds a recent study published in the Journal of the American College of Cardiology.
Carpal tunnel syndrome is the most common compression neuropathy affecting the upper limb, which results from entrapment of the median nerve in the carpal tunnel. It adversely affects daily activities, limits work capacity and impacts on general health and quality of life.
Recent studies have identified transthyretin amyloidosis (ATTR) as a more common cause of heart failure and novel treatments for amyloidosis are emerging. About one-half of patients with ATTR cardiac amyloidosis have a history of CTS.
Emil L. Fosbøl, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark, and colleagues determined the risk of amyloidosis, HF, and other adverse cardiovascular outcomes associated with CTS relative to control subjects without CTS.
For the study, the researchers identified 56,032 patients who underwent surgical treatment for CTS using Danish nationwide registries. The patients were compared with sex- and age-matched cohort (ratio 1:1) from the general population to examine their risk of amyloidosis, HF, and other adverse cardiovascular outcomes.
Also Read: Hormone therapy may reduce risk of carpal tunnel syndrome
Key findings of the study include:
- CTS was associated with a future diagnosis of amyloidosis.
- CTS was associated with a higher incidence of HF, and this held true in the adjusted analysis yielding a hazard ratio of 1.54.
- No significant interaction with sex was found.
- Risk of other adverse outcomes was also associated with CTS (atrial fibrillation, atrioventricular heart block, and pacemaker implantation).
Also Read: Management of carpal tunnel syndrome : American Academy of Orthopaedic Surgeons guidelines
"Patients who undergo surgical treatment for CTS are associated with a higher risk of amyloidosis and HF relative to matched control subjects from the general population. Other cardiovascular outcomes were also increased with CTS," concluded the authors.
To read the complete study log on to https://doi.org/10.1016/j.jacc.2019.04.054
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd